Stryker Corporation $SYK Shares Sold by Financiere des Professionnels Fonds d investissement inc.

Key Points

• Financiere des Professionnels Fonds d'investissement inc. reduced its stake in Stryker Corporation by 5.8%, now holding 20,382 shares worth approximately $8.06 million.
• Analysts have shown a positive outlook for Stryker, with a consensus target price of $431.42 and multiple "buy" ratings from various leading financial institutions.
• Stryker's recent quarterly earnings report revealed a net margin of 12.25% and a revenue increase of 11.1% year-over-year, beating expectations on both EPS and revenue.

Financiere des Professionnels Fonds d investissement inc. trimmed its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 5.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,382 shares of the medical technology company's stock after selling 1,244 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.'s holdings in Stryker were worth $8,064,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Balefire LLC boosted its holdings in shares of Stryker by 37.7% in the second quarter. Balefire LLC now owns 781 shares of the medical technology company's stock valued at $309,000 after acquiring an additional 214 shares during the period. Wolff Financial Management LLC lifted its holdings in shares of Stryker by 12.4% during the second quarter. Wolff Financial Management LLC now owns 10,120 shares of the medical technology company's stock worth $4,004,000 after purchasing an additional 1,113 shares during the period. Fiduciary Alliance LLC lifted its holdings in shares of Stryker by 8.5% during the second quarter. Fiduciary Alliance LLC now owns 7,395 shares of the medical technology company's stock worth $2,926,000 after purchasing an additional 578 shares during the period. Beacon Financial Group acquired a new stake in shares of Stryker during the second quarter worth $208,000. Finally, Czech National Bank lifted its holdings in shares of Stryker by 6.6% during the second quarter. Czech National Bank now owns 84,073 shares of the medical technology company's stock worth $33,262,000 after purchasing an additional 5,195 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.3%

Shares of NYSE SYK traded down $1.23 during midday trading on Friday, hitting $376.61. The stock had a trading volume of 1,924,253 shares, compared to its average volume of 1,391,560. The company has a market capitalization of $143.98 billion, a price-to-earnings ratio of 49.88, a PEG ratio of 2.71 and a beta of 0.93. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average price of $387.77 and a 200 day moving average price of $379.28.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company's revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Insider Activity

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the firm's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on SYK shares. Evercore ISI increased their price target on Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Needham & Company LLC raised their price target on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Truist Financial set a $415.00 price target on Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. Citigroup restated a "buy" rating and issued a $455.00 price target (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Rothschild & Co Redburn assumed coverage on Stryker in a research report on Thursday. They issued a "neutral" rating and a $420.00 price target for the company. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $430.33.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.